PTEN and posterior cortical atrophy: Interestingly, although TOPO is not an FDA approved drug for PCa, IPA analysis predicted PCa signaling (p = 1.40E-14) and PTEN (p = 1.53E-13) signaling pathways as targets for METRO TOPO treatment (Supplementary Table S2).